|
|
Volumn 23, Issue 11, 2005, Pages 1323-1324
|
|
First-in-class biologic to enter rheumatoid arthritis fray
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE;
ABATACEPT;
ADALIMUMAB;
ADENOSINE A3 RECEPTOR AGONIST;
AMG 714;
ANTIRHEUMATIC AGENT;
BELIMUMAB;
CD20 ANTIBODY;
CERTOLIZUMAB PEGOL;
CHEMOKINE RECEPTOR ANTAGONIST;
CHEMOKINE RECEPTOR CCR 2 ANTIBODY;
ETANERCEPT;
GOLIMUMAB;
HYBRID PROTEIN;
INFLIXIMAB;
INTERLEUKIN 15 ANTIBODY;
INTERLEUKIN 6 ANTIBODY;
INTERLEUKIN 6 RECEPTOR ANTIBODY;
MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR;
MLN 1202;
MM 093;
PROTEIN DNAJ;
RECOMBINANT HUMAN ALPHA FETOPROTEIN;
RITUXIMAB;
SCIO 469;
TUMOR NECROSIS FACTOR ANTIBODY;
UNCLASSIFIED DRUG;
VX 702;
AUTOIMMUNE DISEASE;
CLINICAL TRIAL;
DRUG APPROVAL;
DRUG COST;
DRUG EFFICACY;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
MALIGNANT NEOPLASTIC DISEASE;
NOTE;
PRIORITY JOURNAL;
RHEUMATOID ARTHRITIS;
TREATMENT FAILURE;
TREATMENT OUTCOME;
TUBERCULOSIS;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
CLINICAL TRIALS;
DRUG INDUSTRY;
HUMANS;
IMMUNOCONJUGATES;
IMMUNOTHERAPY;
RECEPTORS, TUMOR NECROSIS FACTOR;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 27944494866
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt1105-1323 Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|